Santhera Pharms Hldgs Ltd

1.400000.00Vol 12.50K1Y Perf -55.41%
Nov 30th, 2021 20:05
BID0.0000 ASK0.0000
Open1.4000 Previous Close1.4000
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
     22.96
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
     13.89
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
0.71 
Earnings Rating
Market Cap- 
Earnings Date
-
Alpha-0.07 Standard Deviation0.28
Beta2.49 

Today's Price Range

1.40001.4000

52W Range

1.37005.6100

5 Year PE Ratio Range

-4.400084.500

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.00%
1 Month
0.72%
3 Months
-38.60%
6 Months
-51.22%
1 Year
-55.41%
3 Years
-87.18%
5 Years
-96.76%
10 Years
0.00%

TickerPriceChg.Chg.%
SPHDF1.40000.00000.00
AAPL171.185.86003.54
GOOG2 960.7384.80002.95
MSFT334.928.73002.68
XOM62.270.69001.12
WFC50.251.44002.95
JNJ163.000.06000.04
FB322.814.94001.55
GE97.551.54001.60
JPM162.572.41001.50
Financial StrengthValueIndustryS&P 500US Markets
0.20
0.30
0.66
5.19
-2.60
Leverage Ratio 38.50
ProfitabilityValueIndustryS&P 500US Markets
11.70
-344.90
-288.00
-200.70
-38.10
RevenueValueIndustryS&P 500US Markets
12.67M
0.23
1.78
32.88
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume12.50K
Shares Outstanding0
Shares Float17.52M
Trades Count1
Dollar Volume17.50K
Avg. Volume3.85K
Avg. Weekly Volume10.14K
Avg. Monthly Volume4.00K
Avg. Quarterly Volume3.86K
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Santhera Pharms Hldgs Ltd

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company focused on the development and commercialization of products for the treatment of mitochondrial and neuromuscular diseases, an area which includes many orphan and niche indications with high unmet medical need. It has one operating segment, namely the development and commercialization of products for the treatment of neuro-ophthalmological, pulmonary and neuromuscular diseases. The company derives the majority of its revenue from the European Union.

CEO:

Telephone: +41 619068950

Address: Hohenrainstrasse 24, Pratteln 4133, , CHE

Number of employees: 119

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

40%60%

Bearish Bullish

50%50%

News